NiQuitin Mini 4mg mint lozenges
- Name:
NiQuitin Mini 4mg mint lozenges
- Company:
Chefaro Ireland Ltd
- Active Ingredients:
- Legal Category:
Supply through general sale
Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 25/06/20
(Click to Download)Click on this link to Download PDF directly
Chefaro Ireland Ltd
Company Products
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 25 June 2020 SmPC
Reasons for updating
- Change to section 3 - Pharmaceutical form
- Change to section 6.1 - List of excipients
- Change to section 6.3 - Shelf life
- Change to section 10 - Date of revision of the text
Legal category: Supply through general sale
Updated on 25 June 2020 PIL
Reasons for updating
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - date of revision
- Change of inactive ingredient
Updated on 31 July 2019 PIL
Reasons for updating
- Change to section 6 - what the product looks like and pack contents
- Change to section 6 - manufacturer
- Change to section 6 - date of revision
- Change to marketing authorisation holder
Updated on 31 July 2019 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Supply through general sale
Updated on 11 April 2019 PIL
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - what the product contains
Updated on 10 April 2019 SmPC
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.3 - Contraindications
- Change to section 4.4 - Special warnings and precautions for use
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.7 - Effects on ability to drive and use machines
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.1 - List of excipients
- Change to section 6.6 - Special precautions for disposal and other handling
Legal category: Supply through general sale
Updated on 14 January 2019 PIL
Reasons for updating
- Change to section 6 - manufacturer
Updated on 13 January 2019 SmPC
Reasons for updating
- Change to MA holder contact details
Legal category: Supply through general sale
Updated on 8 November 2016 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Chefaro Ireland DAC, Treasury Building, Lower Grand Canal Street, Dublin 2, Ireland
Updated on 8 November 2016 PIL
Reasons for updating
- New PIL for new product
Updated on 8 November 2016 SmPC
Reasons for updating
- New SmPC for new product
Legal category: Supply through general sale
Updated on 8 November 2016 PIL
Reasons for updating
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 28 July 2016 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 8 - MA number
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Chefaro Ireland Limited First Floor, Block A The Crescent Building Northwood Office Park Dublin 9
Ireland
8 MARKETING AUTHORISATION NUMBER
PA1186/018/012
Updated on 11 July 2016 PIL
Reasons for updating
- Change to MA holder contact details
Updated on 10 July 2015 SmPC
Reasons for updating
- Change to section 7 - Marketing authorisation holder
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Section 7
Marketing Authorisation Holder address updated to:
12 Riverwalk,
Citywest Business Campus,
Dublin 24,
Ireland
Updated on 13 November 2014 PIL
Reasons for updating
- Improved electronic presentation
Updated on 9 December 2013 SmPC
Reasons for updating
- Change to section 10 - Date of revision of the text
- Change to section 4.9 - Overdose
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Overdosage - update of info
Updated on 21 August 2013 SmPC
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Updated on 22 November 2012 PIL
Reasons for updating
- Change to side-effects
- Change to date of revision
Updated on 15 June 2011 SmPC
Reasons for updating
- Change to section 4.8 - Undesirable effects
- Change to section 10 - Date of revision of the text
Legal category: Supply through general sale
Free text change information supplied by the pharmaceutical company
Certain symptoms which have been reported such as depression, irritability, anxiety, increased appetite and insomnia may be related to withdrawal symptoms associated with smoking cessation. Subjects quitting smoking by any means could expect to suffer from headache, dizziness, sleep disturbance, increased coughing or a cold.
|
Immune system disorder |
|
|
|
|
|
|
Very rare (<1/10000): anaphylactic reactions |
|
|
|
Updated on 13 August 2010 PIL
Reasons for updating
- New PIL for medicines.ie
Updated on 27 November 2009 SmPC
Reasons for updating
- New SPC for new product
Legal category: Supply through general sale